Today, the Pres. & CFO of Alimera (NASDAQ: ALIM), Richard Eiswirth, bought shares of ALIM for $10.5K.
This recent transaction increases Richard Eiswirth’s holding in the company by 6.18% to a total of $178.6K.
See today’s analyst top recommended stocks >>
Based on Alimera’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $9.8 million and GAAP net loss of $7.68 million. In comparison, last year the company earned revenue of $6.62 million and had a GAAP net loss of $6.74 million. Currently, Alimera has an average volume of 220.8K.
Starting in September 2016, ALIM received 18 Buy ratings in a row. Five different firms, including Cantor Fitzgerald and Citigroup, currently also have a Buy rating on the stock.
The insider sentiment on Alimera has been positive according to 17 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. It operates through the U.S. and International geographic segments. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration, and retinal vein occlusion.
